AstraZeneca Files Patent Infringement Suits Against Seven Generic Drugmakers Over Crestor
This article was originally published in The Pink Sheet Daily
Executive Summary
Nine companies in all have filed ANDAs with Paragraph IV certification against a Crestor patent, but two indicated they will not launch generic rosuvastatin prior to the patent’s expiry, AstraZeneca tells DAILY.